Coltac Therapeutics
- Biotech or pharma, therapeutic R&D
Coltac is committed to discovering the next generation of molecular glues, for protein degradation, by harnessing our BOND+ platform - combining in-silico with the power of our bacteria-based, synthetic positive selection screening system for new molecular glues for TPD.
Our rapid transition from virtual screening to high-throughput bacterial validation accelerates the development of next-generation drugs for oncology and other therapeutic areas. Coltac is advancing 3 programs, with 2 high-value oncology targets, and 1 non-onc, based on unique ligases.
Coltac is venture-backed by aMoon and IBF.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}